Valve Center, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
Clinique Pasteur, Toulouse, France.
Int J Cardiol. 2024 Dec 15;417:132569. doi: 10.1016/j.ijcard.2024.132569. Epub 2024 Sep 19.
Raphe-type bicuspid aortic valve (BAV) is a potential hostile scenario in trans-catheter aortic valve replacement (TAVR) due to pronounced calcium burden, possibly associated with tapered valve configuration. Trans-Catheter heart valve (THV) sizing strategy (annular vs. supra-annular) is controversial in this valve subtype.
To describe the phenotypical characteristics of severe, tapered, raphe-type, BAV stenosis undergoing TAVR and to explore safety and efficacy of modern-generation THVs, analysing the impact of annular and supra-annular sizing strategies on short- and mid-terms outcomes.
This is a retrospective, multicenter registry enrolling consecutive stenotic Sievers type 1 BAV treated with TAVR. Study population was divided into tapered and non-tapered configuration according to MSCT analysis. Matched comparison between annular and supra-annular sizing groups was performed in tapered population.
From January 2016 to June 2023, 897 patients were enrolled. Of them, 696 patients displayed a tapered configuration. Of those, 510 received a THV according to annular sizing. After propensity score matching 186 matched pairs were selected. Technical success (96.2 % vs 94.1 %, OR 1.61 [0.61-4.24], p = 0.34), 30-day device success (83.6 % in both groups, OR 1.42 [0.78-2.57], p = 0.25) and 30-day early safety (71.8 % vs 70.5 %, OR 1.07 [0.68-1.68], p = 0.78) were similar between the annular and supra-annular sizing groups; a higher post-TAVR gradient was observed in supra-annular group, although it was only 2 mmHg mean. At mid-term follow-up, the rate of clinical efficacy was 84.7 %.
TAVR with modern-generation devices is safe and effective for tapered raphe-type BAV, showing comparable results for annular and supra-annular sizing strategies.
由于严重的钙负荷,跨导管主动脉瓣置换术(TAVR)中出现中隔型双叶主动脉瓣(BAV)是一种潜在的敌对情况,这可能与锥形瓣膜结构有关。在这种瓣膜亚型中,经导管心脏瓣膜(THV)的尺寸策略(环形与瓣上)存在争议。
描述经 TAVR 治疗的严重、锥形、中隔型、BAV 狭窄的表型特征,并探讨现代一代 THV 的安全性和有效性,分析环形和瓣上尺寸策略对短期和中期结果的影响。
这是一项回顾性、多中心登记研究,纳入了接受 TAVR 治疗的连续狭窄性 Sievers 1 型 BAV 患者。根据 MSCT 分析,将研究人群分为锥形和非锥形结构。在锥形人群中,对环形和瓣上尺寸组进行了匹配比较。
从 2016 年 1 月至 2023 年 6 月,共纳入 897 例患者。其中,696 例患者呈现锥形结构。其中,510 例患者根据环形尺寸接受了 THV。经过倾向评分匹配后,选择了 186 对匹配对。技术成功率(96.2% vs 94.1%,OR 1.61 [0.61-4.24],p=0.34)、30 天器械成功率(两组均为 83.6%,OR 1.42 [0.78-2.57],p=0.25)和 30 天早期安全性(71.8% vs 70.5%,OR 1.07 [0.68-1.68],p=0.78)在环形和瓣上尺寸组之间相似;瓣上组的术后 TAVR 梯度较高,但仅高 2mmHg。在中期随访中,临床疗效的发生率为 84.7%。
对于锥形中隔型 BAV,现代一代设备的 TAVR 是安全有效的,环形和瓣上尺寸策略的结果相似。